Skip to main content

Table 6 Factors associated with biochemical recurrence in entire cohort and each risk group

From: Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy

  Entire cohort
  Univariate analyses   Multivariate analyses
  HR 95%CI p-value HR 95%CI p-value
PSAD >0.345 vs ≤0.345 ng/ml/ 3.105 1.669–5.776 <0.001    
% positive cores >21.4 vs ≤21.4% 2.490 1.363–4.551 0.003    
% dominant side >37.5 vs ≤37.5% 3.793 2.016–7.136 <0.001 2.648 1.369–5.121 0.004
% cancer extent >55.6 vs ≤55.6% 3.301 1.778–6.130 <0.001 2.505 1.324–4.741 0.005
NCCN risk high vs intermediate 2.517 1.391–4.555 0.002 2.069 1.129–3.791 0.019
  Intermediate-risk
  Univariate analyses   Multivariate analyses
  HR 95%CI p-value HR 95%CI p-value
PSAD >0.190 vs ≤0.190 ng/ml/cc 2.040 0.803–5.185 0.134    
% positive cores >21.4 vs ≤21.4% 3.910 1.485–10.29 0.006 3.910 1.485–10.29 0.006
% dominant side >36.4 vs ≤36.4% 1.111 0.871–1.418 0.398    
% cancer extent >57.1 vs ≤57.1% 3.207 1.288–7.984 0.012    
  High-risk
  Univariate analyses   Multivariate analyses
  HR 95%CI p-value HR 95%CI p-value
PSAD >0.345 vs ≤0.345 ng/ml/cc 3.121 1.428–6.824 0.004 3.103 1.373–7.012 0.006
% positive cores >35.0 vs ≤35.0% 3.005 1.374–6.572 0.006    
% dominant side >40.0 vs ≤40.0 2.404 1.089–5.306 0.030    
% cancer extent >55.6 vs ≤55.6% 2.788 1.218–6.382 0.015    
  1. HR Hazard ratio, 95%CI 95% confidence interval, % dominant side % positive cores from dominant side, % cancer extent maximum % of cancer extent in each positive core, Bold indicates statistically significant